Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALL COMMON, Menon has years of credibility with the FDA!!! Do you understand that point!!!! And that's the only reason he was allowed to present the recent data to FDA!!!
you are welcome!! anytime!!
nano, get on the phone with Leo and resolve Menon's issue. You are the only one on this board capable of asking tough questions on patents! TIA
Does it mean he has patent #s issued in his name?? em
Kittie, I hope it goes down to $1.99. My prayers are with you!! em
217K Volume!!!!!!!!!!!!!!! em
yes. and Dr.Seymour will round it out a month later in London, England.
quit being acrimonious and explain what you post!!! I certainly can't decipher your verbosity!!! go take a refresher course in writing!! I certainly can't read your mind. Get civil!
O.K!! here's a copy of your post with Menon's name highlighted!!
-------------------------------------------------------------
Cryptophycin compound
Abstract
The present invention provides antitumor methods, formulations, and compounds comprising a cryptophycin.
--------------------------------------------------------------------------------
Inventors: Corbett; Thomas Hughes (Grosse Pointe Park, MI), Moore; Richard Elliott (Honolulu, HI), Liang; Jian (Honolulu, HI)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Wayne State University (Detroit, MI)
University of Hawaii (Honolulu, HI)
Appl. No.: 09/915,638
Filed: July 26, 2001
--------------------------------------------------------------------------------
Current U.S. Class: 514/183 ; 540/451
Current International Class: C07D 273/00 (20060101)
Field of Search: 514/183 540/451
--------------------------------------------------------------------------------
References Cited [Referenced By]
--------------------------------------------------------------------------------
U.S. Patent Documents
6013626 January 2000 Moore et al.
6180679 January 2001 Shih et al.
Foreign Patent Documents
WO 98/08505 Mar., 1998 WO
Other References
Chen B. et al, Cellular Uptake of a Novel Cytotoxic Agent, Cryptophycin-52, By Human THP-1 Leukemia Cells and H-125 Lung Tumor Cells, Int. J. Cancer (1998), 77, pp869-873. .
Panda D. et al, Mechanism of Action of the Unusually Potent Microtubule Inhibitor Cryptophycin 1, Biochemisty (1997), 36, pp12948-12953. .
Smith C. et al, Cryptophycin: A New Antimicrotubule Agent Active Against Drug-Resistant Cells, Cancer Research (Jul. 15, 1994), 54, pp3779-3784. .
Wagner M. et al, In Vitro Pharmacology of Cryptophycin 52 (LY355703) in Human Tumor Cell Lines, Cancer Chemother. Pharmacol. (1999), 43, pp115-125. .
Panda D. et al., Antiproliferative mechanism of action of cryptophycin-52: Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends, Proc. Natl. Acad. Sci. (Aug. 1998), 95:9313-9318. .
Teicher B. et al., Cryptophycin 52 and Cryptophycin 55 in Sequential and Simultaneous Combination Treatment Regimens in Human Tumor Xenografts, In Vivo (2000), 14:471-480. .
Moore R. et al., The Search for New Antitumor Drugs from Blue-Green Algae, Current Pharmaceutical Design (1996), 2:317-330. .
Liang J. et al., Synthesis of Cryptophycin 52 Using the Sharpless Asymmetric Dihydroxylation: Diol to Epoxide Transformation Optimized for a Base-Sensitive Substrate, J. Org. Chem. (2000), 65:3143-3147. .
Gardinier K. et al., Enantiospecific Total Synthesis of the Potent Antitumor Macrolides Cryptophycins 1 and 8, J. Org. Chem (1997), 62(21):7098-7099. .
Norman B. et al., Total Synthesis of Cryptophycin Analogues. Isosteric Replacement of the C-D Ester, J. Org. Chem. (1998), 63(15):5288-5294. .
Golakoti T. et al., Structure Determination, Conformational Analysis, Chemical Stability Studies, and Antitumor Evaluation of the Cryptophycins. Isolation of 18 New Analogs from Nostoc sp. Strain GSV 224, J. Am. Chem. Soc. (1995), 117:12030-12049. .
Menon K. et al., Antitumor activity of cryptophycins: effect of infusion time and combination studies, Cancer Chemother. Pharmacol. (2000), 46:142-149. .
Georg G. et al., Halohydrin Analogues of Cryptophycin 1: Synthesis and Biological Activity, Bioorganic & Medicinal Chemistry Letters 8 (1998), pp1959-1962..
Primary Examiner: Kifle; Bruck
Attorney, Agent or Firm: Merchant & Gould P.C.
What's the point?? If Menon's name is there please highlight it or if it is referencing MEnon's work please highlight!
abbam, I was told the company will not address each shareholder's question individually and via email, at least till the 10SB is filed. However any questions or concerns will be addressed in PRs which are available to everyone at the same time. I feel this is O.K as I don't want to see them spend time answering frivilous emails.
Doc, take a look at this PR and see if I stated correct....
NanoViricides CEO Releases Details of ''Just In Time'' Manufacturing; Company to Begin Animal Testing of New Drugs This Fall
PrintE-mailDisable live quotesRSSDigg itDel.icio.usLast Update: 7:30 AM ET Aug 30, 2006
WEST HAVEN, Conn., Aug 30, 2006 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink Sheets: NNVC) CEO Dr. Eugene Seymour, MD, MPH, says the company is poised to usher in a new era of "just in time manufacturing" of antiviral medications.
In an interview Monday with Wall Street Reporter senior analyst Ian Roberts, Seymour said NanoViricides will be able to rapidly respond to deadly outbreaks." The full interview will be available at wallstreetreporter.com for the next four days.
The relatively simple two-part structure is what makes a nanoviricide(TM) type drug so adept at rapid response.
"The beauty of this whole system is that the nanomicelle(TM) is the same for every viral target. The only thing that changes is the targeting molecule," said Seymour, which could be stockpiled. "Say there's an outbreak of a viral disease for which we have already created and tested a nanoviricide(TM), all we would then do is take the targeting molecule off the shelf, attach it to the nanomicelle, package it and you've got a drug treatment for that disease. That can happen in a matter of days."
Seymour said if NanoViricides' approach is successful it will mark "a completely new way of defining manufacturing in the pharmaceutical industry."
The company has four drugs that will undergo a round of pre-clinical animal testing this fall in Vietnam. They include:
-- FluCide(TM)-I - Expected to work against all influenzas.
-- AviFluCide(TM) -- Designed specifically to target the H5N1 strain of avian influenza.
-- AviFluCide-HP(TM) -- Designed to attack the highly pathogenic influenza subgroup that is continuously re-emerging and changing.
-- RabiCide(TM) - Engineered to attack rabies, which remains a major subtropical killer.
Comparing the company's drugs to microscopic cruise missiles, Seymour said all nanoviricide(TM) drugs are composed of two main components. Scientists begin with a 20-nanometer cluster of molecules dubbed a "nanomicelle(TM)", which acts as the vehicle. They then attach the second component, a stripped-down antibody known as a ligand or targeting molecule. This targeting molecule acts as the vehicle's guidance system. The ligand then attaches to a virus, allowing the nanomicelle(TM) to completely encompass the virus envelope and its deadly RNA-replicating core.
"And now that you have the (virus) RNA trapped within this new structure, it is simply digested by the cells of the immune system and turned into its basic chemical components," said Seymour.
NanoViricides is currently focused on expanding its roster of scientists while locating additional research and development facilities, as well as a manufacturing plant.
About NanoViricides - http://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
SOURCE: NanoViricides, Inc.
NanoViricides, Inc. Leo Ehrlich, 917-853-6440 leo@nanoviricides.com Copyright Business Wire 2006
Doc, they have started the preclinical animal studies in VN in Fall!!!
NanoViricides, Inc. Finds FluCide(TM)-I Superior to Oseltamivir in Preliminary Animal Studies, Presents Data at the 7th Annual Targeted Nano-delivery Conference
A Company to Release Financials at the End of This Week
PrintE-mailDisable live quotesRSSDigg itDel.icio.usLast Update: 12:52 PM ET Oct 18, 2006
WEST HAVEN, Conn., Oct 18, 2006 (BUSINESS WIRE) -- NanoViricides (Pink Sheets: NNVC) President and Chairman, Dr. Anil Diwan, presented preliminary data on animal studies that compare nanoviricides drug candidates with oseltamivir (Tamiflu(R) Roche) on Friday, Oct. 13th at the 7th Annual Targeted Nano-delivery Conference in Baltimore, MD.
"Mice treated with the FluCide(TM)-I nanoviricide drug survived 186 hours (7.75 days, or 2.75 days more than control mice), whereas those treated with oseltamivir at twice the usual amounts normally used in such studies survived for only 151 hours (6.3 days, or only about 1.3 days longer than control). The experiment was designed with an aggressive infection level of common influenza such that control mice survived only 120 hours (5.0 days)," Dr. Diwan reported at the Conference. He also reported that all nanoviricides drug candidates tested were found to be superior to oseltamivir in this study. The studies were conducted by Dr. Krishna Menon under the auspices of KARD Scientific, Inc. in a blind study at a facility in Cambridge, MA. Dr. Mennon commented, "No obvious toxic effects were observable for the nanoviricide drugs. Therefore we believe the dosage of the nanoviricide drugs can be substantially increased to their therapeutic levels. This is expected to lead to a greatly enhanced therapeutic effect. This test was designed only to establish comparative baselines. Future experiments will be designed to assess the full therapeutic dosage levels and their efficacies."
NanoViricides, Inc. believes that at present no other anti-influenza drug candidate has shown results that are anywhere close to the results obtained with nanoviricides, both in terms of the in vitro data in H5N1 (presented earlier) and the in vivo data against common influenza.
In other news, NanoViricides announced it is on target to release its financials by the end of this week.
About NanoViricides - http://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
SOURCE: NanoViricides, Inc.
NEws out!!!
should be onto an upward move early next week!!em
I think this issue should be closed...no more posts on this topic. em
Matty, for a change why don't you do some DD for us...take up the issue with Eli Lilly and see if they object to Dr. Menon's claims?? Will ya??? Hurry please!!!
Do you know the verification process?? Probably Don can help out???
probably the DOC can take it up with NNVC and have it verified or clarified!! jmo.
O.K!! O.K!!! so what??? they were not able to anticipate all the issues!! stop being a bore, will ya??
LOL!!
LOL!! especially since there seems to be no resolution!!! Probably it should end with 'no resolution' whenever it comes into play!!! jmo
there probably is some truth to that. Gross underestimation of effort!!!!
It certainly is a long, long time since I have seen this print!! I guess this was placed inside of the album or on the cover, I forget.
CSHD tanking???
SCHADENFREUDE please bring the price down so that us poor retail investors can get in!!! TIA
Goldman Sachs! em
besides there is no point bring back or trying to resolve the same issues over and over again, be it here or RB!!!jmo
that's a good pump!! em
common fog, you got to give what you find and not what the analysts are picking!!!!! O.K.O.K!!! just kidding!!! might as well as add XOM to it!!! both XOM and COP are analysts picks (GS).
RonnieD, TA can flip/flop at the toss of a coin, especially for pinks which are news driven. I agree FA is the best way to decide about one's investment. However, keep in mind that there are rogue manipulators in the pinksheet market!
so far, 1 well good and 1 well dry!! em
does that mean we have a PR tomorrow??? em
I guess we need Schaden's help!! LOL!
west, go get them!! em
I understand and thanks for your efforts. em
I don't expect anyone nor you to follow me!! But I am just saying what happens in the market. Now, having said that it may never experience a sell off, other than a minor one!!
This was clear manipulation by WillyWizard!!! Their website posts all the SEC link, however they failed to realize that the S-8 was not seen on EDGAR website!! So how can they tout the S-8??? Beats me. An event that calls for SEC investigation. jmo
Redmann, different people have varying risk profiles. Your assessment probably suits your profile. Your DD has not covered all points adequately. I think you should read ABER's annual report. ABER has unlimited A/S and they have 60M O/S. Also the report states that DEMAND far exceeds SUPPLY. Just because GBDX were not profiatble in the past does not mean they will not be profitable again. This time around they have experience behind them. Also as mentioned demand exceeds supply. In addition DeBeers will not conduct business inthe US at the least for next 2 yrs. And finally Diamonds are luxury items and command healthy premiums. This can be a winner for very small upfront investment. jmo